Protective Arm of the Renin Angiotensin System (RAS) (eBook)

Functional Aspects and Therapeutic Implications

Robson Augusto Souza dos Santos, U. Muscha Steckelings, Thomas Unger (Herausgeber)

eBook Download: PDF | EPUB

2015 | 1. Auflage
316 Seiten
Elsevier Science (Verlag)
978-0-12-801485-1 (ISBN)

Infos

The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin-angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1-7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications. - Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor - Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas. - Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases - Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.

Textauszug

Contributors

Marie-Isabel Aguilar     Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia

Natalia Alenina

Max-Delbrueck-Center for Moleculare Medicine (MDC), Berlin-Buch, Germany

Federal University of Minas Gerais, Belo Horizonte, Brazil

Instituto Nacional de Ciência e Tecnologia em, NanoBiofarmacêutica (NanoBIOFAR), Belo Horizonte, Brazil

Peter W. Angus     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia

Michael Bader

Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany

Charité Medical Faculty, Berlin, Germany

Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Institute for Biology, University of Lübeck, Germany

Ana Paula Correa Oliveira Bahia     Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Dhaniel Baraldi     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia

Lívia Corrêa Barroso     Departamento de Bioquimica e Imunologia, UFMG, Belo Horizonte, Minas Gerais, Brazil

Lenice Becker     Sport Center of UFOP, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil

Douglas M. Bennion     Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, USA

Serge P. Bottari

Laboratory for Fundamental and Applied Bioenergetics, INSERM U1055, Université Grenoble—Alpes

Radioanalysis Unit, Institute for Biology and Pathology, CHU de Grenoble, Grenoble, France

Peter Buehlmayer     Hangstrasse 18, CH-4144 Arlesheim, Switzerland

Maria J. Campagnole-Santos     Department of Physiology and Biophysics, INCT-Nanobiofar, Institute of Biological Sciences, Federal University of Minas Gerais-UFMG, Brazil

Robert M. Carey     Department of Medicine, University of Virginia, Charlottesville, Virginia, USA

Harshita Chodavarapu     Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

Leoluca Criscione     MangiaSano Consulting, Rümelinbachweg 10, CH-4054 Basel, Switzerland

Juraj Culman     Institute of Experimental and Clinical Pharmacology, University Hospitals of Schleswig-Holstein, Campus Kiel, Kiel, Germany

Björn Dahlöf     Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden

Leon Alexander Danyel     Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany

Marc de Gasparo     Cardiovascular & Metabolic Syndrome Adviser, Rossemaison, Switzerland

Mark Del Borgo     Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia

Kate M. Denton     Department of Physiology, Monash University, Clayton Victoria 3800, Australia

Isha S. Dhande     University of Hosuton, Houston, Texas, USA

Gere S. diZerega

US Biotest, San Luis Obispo

Keck School of Medicine, Los Angeles, CA, USA

Fernando Pablo Dominici     Department of Biological Chemistry, IQUIFIB, University of Buenos Aires, Buenos Aires, Argentina

Adelina M. dos Reis     Department of Physiology & Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Victor J. Dzau     Institute of Medicine of the National Academies, Washington, DC, USA

Veronica Valero Esquitino     Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany

Anderson J. Ferreira     Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, MG 31270-901, Brazil

Anna Foryst-Ludwig     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Sébastien Foulquier     CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands

Rodrigo A. Fraga-Silva     Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, Lausanne, Vaud, Switzerland

Frédéric Frézard     Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Pascal Furet     Novartis Institute for Biochemical Research, CH-4002 Basel, Switzerland

Patricia E. Gallagher     Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

Lie Gao     Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Tracey A. Gaspari     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia

Mariela M. Gironacci     Department of Biological Chemistry, IQUIFIB-CONICET, University of Buenos Aires, Buenos Aires, Argentina

Anders Hallberg     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden

Chandana B. Herath     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia

Lucinda M. Hilliard     Department of Physiology, Monash University, Clayton Victoria 3800, Australia

Masatsugu Horiuchi     Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Shitsukawa, Ehime, Japan

Tahir Hussain     University of Hosuton, Houston, Texas, USA

Rebecka Isaksson     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden

Emma S. Jones     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia

Elena Kaschina     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Michael Katovich     Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA

Ulrich Kintscher     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Mats Larhed     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden

Eric Lazartigues     Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

Kai Y. Mak     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia

Nephtali Marina     Department of Clinical Pharmacology and Experimental Therapeutics, University College London, London,...

Produkt-Details

• Erscheint lt. Verlag: 18.4.2015
• Sprache: englisch
• Themenwelt: Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Physiologie
• ISBN-10: 0-12-801485-7 / 0128014857
• ISBN-13: 978-0-12-801485-1 / 9780128014851